Logo image of CYCN

CYCLERION THERAPEUTICS INC (CYCN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CYCN - US23255M2044 - Common Stock

1.36 USD
-0.16 (-10.53%)
Last: 1/15/2026, 8:00:01 PM
1.32 USD
-0.04 (-2.94%)
Pre-Market: 1/16/2026, 4:05:26 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CYCN. CYCN was compared to 528 industry peers in the Biotechnology industry. CYCN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYCN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CYCN has reported negative net income.
  • CYCN had a negative operating cash flow in the past year.
  • CYCN had negative earnings in each of the past 5 years.
  • In the past 5 years CYCN always reported negative operating cash flow.
CYCN Yearly Net Income VS EBIT VS OCF VS FCFCYCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • CYCN has a better Return On Assets (-21.11%) than 75.00% of its industry peers.
  • CYCN has a Return On Equity of -23.06%. This is amongst the best in the industry. CYCN outperforms 81.25% of its industry peers.
Industry RankSector Rank
ROA -21.11%
ROE -23.06%
ROIC N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
CYCN Yearly ROA, ROE, ROICCYCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CYCN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CYCN Yearly Profit, Operating, Gross MarginsCYCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CYCN has been increased compared to 1 year ago.
  • CYCN has more shares outstanding than it did 5 years ago.
  • CYCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CYCN Yearly Shares OutstandingCYCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
CYCN Yearly Total Debt VS Total AssetsCYCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -33.06, we must say that CYCN is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -33.06, CYCN is not doing good in the industry: 88.26% of the companies in the same industry are doing better.
  • There is no outstanding debt for CYCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.06
ROIC/WACCN/A
WACCN/A
CYCN Yearly LT Debt VS Equity VS FCFCYCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

  • CYCN has a Current Ratio of 5.78. This indicates that CYCN is financially healthy and has no problem in meeting its short term obligations.
  • CYCN has a better Current ratio (5.78) than 60.80% of its industry peers.
  • CYCN has a Quick Ratio of 5.78. This indicates that CYCN is financially healthy and has no problem in meeting its short term obligations.
  • CYCN's Quick ratio of 5.78 is fine compared to the rest of the industry. CYCN outperforms 62.12% of its industry peers.
Industry RankSector Rank
Current Ratio 5.78
Quick Ratio 5.78
CYCN Yearly Current Assets VS Current LiabilitesCYCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 46.04% over the past year.
  • Measured over the past years, CYCN shows a very negative growth in Revenue. The Revenue has been decreasing by -15.01% on average per year.
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.73%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%353.61%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CYCN Yearly Revenue VS EstimatesCYCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2024 1M 2M 3M 4M
CYCN Yearly EPS VS EstimatesCYCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CYCN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CYCN Price Earnings VS Forward Price EarningsCYCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CYCN Per share dataCYCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CYCN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CYCLERION THERAPEUTICS INC

NASDAQ:CYCN (1/15/2026, 8:00:01 PM)

Premarket: 1.32 -0.04 (-2.94%)

1.36

-0.16 (-10.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-02
Inst Owners7.07%
Inst Owner Change0%
Ins Owners18.74%
Ins Owner Change0%
Market Cap5.34M
Revenue(TTM)2.85M
Net Income(TTM)-2.20M
Analysts82.86
Price TargetN/A
Short Float %4.68%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.87
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.73
BVpS2.43
TBVpS2.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.11%
ROE -23.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-104.94%
ROA(5y)-93.87%
ROE(3y)-166.99%
ROE(5y)-147.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.78
Quick Ratio 5.78
Altman-Z -33.06
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.73%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-20.23%
Revenue growth 5Y-15.01%
Sales Q2Q%353.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y62.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y94.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.86%
OCF growth 3YN/A
OCF growth 5YN/A

CYCLERION THERAPEUTICS INC / CYCN FAQ

What is the ChartMill fundamental rating of CYCLERION THERAPEUTICS INC (CYCN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CYCN.


Can you provide the valuation status for CYCLERION THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to CYCLERION THERAPEUTICS INC (CYCN). This can be considered as Overvalued.


How profitable is CYCLERION THERAPEUTICS INC (CYCN) stock?

CYCLERION THERAPEUTICS INC (CYCN) has a profitability rating of 1 / 10.